TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26261190

Group type: EXPERIMENTAL
Intervention: Group-based physical exercise at work during working hours
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physical exercise at home during leisure time
Number of subjects: 200
Study: 22942376

Group type: EXPERIMENTAL
Intervention: Proxy assent process in a randomised controlled trial of influenza vaccination
Number of subjects: 968
Study: 21442807

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shiqizhui (Extra) in the premenstrual period (group A, n = 20)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Acupuncture at Shiqizhui (Extra) when pain occurs (group B, n = 20)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Blank group (group C, n = 40)
Number of subjects: 80
Study: 19674471

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 21998085

Group type: EXPERIMENTAL
Intervention: Canalith repositioning procedure
Number of subjects: 63

Group type: COMPARATOR
Intervention: Typical BPPV (comparison group)
Number of subjects: 63
Study: 16334720

Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Liuwei Dihuang Wan (Bolus of the Six Drugs Including Rehmanniae)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral prednisone
Number of subjects: 100
Study: 12871257

Group type: EXPERIMENTAL
Intervention: Self-reported voice problems
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Expert voice rating
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Objective voice assessment (amplitude perturbation)
Number of subjects: 204
Study: 9523308

Group type: EXPERIMENTAL
Intervention: Risedronate solution 40 mg in 30 mL of water administered directly into the stomach, second part of the duodenum, or terminal ileum over 1 minute (study A)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Risedronate solution 40 mg in 30 mL of water administered directly into the second part of the duodenum over 1 minute and over 1 hour (study B)
Number of subjects: 8
Study: 8595642

Group type: EXPERIMENTAL
Intervention: Gemfibrozil 600 mg twice daily
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 to 40 mg twice daily
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gemfibrozil
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 9
Study: 2510372

Group type: EXPERIMENTAL
Intervention: Enteral nutrient formula (Osmolite)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Food diet (F)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both diets (ENF and F)
Number of subjects: 0
Study: 785178

Group type: EXPERIMENTAL
Intervention: Sisomicin 75 or 100mg (1.4 mg/kg) single intramuscular injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sisomicin 50 or 75mg (1.9 or 2.1 mg/kg) b.i.d.
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Sisomicin (both dosages)
Number of subjects: 30
Study: 11246243

Group type: EXPERIMENTAL
Intervention: Low-volume ventriculography (15 mL/sec for 1 sec)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard-volume ventriculography (15 mL/sec for 3 sec)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Low-volume ventriculography
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard-volume ventriculography
Number of subjects: 102
Study: 30613000

Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBT)
Number of subjects: 436
Study: 29332218

Group type: EXPERIMENTAL
Intervention: Sleep hygiene training (two sessions)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 128
Study: 27450231

Group type: EXPERIMENTAL
Intervention: Greenselect Phytosome® (150 mg/dose) and piperine (15 mg/dose)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 25368724

Group type: EXPERIMENTAL
Intervention: IvIg (0.4 g/kg/day for 5 days)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PE (4 PE during 10-14 days)
Number of subjects: 41
Study: 23469601

Group type: EXPERIMENTAL
Intervention: Qiyao Xiaoke Capsule (QXC), 0.4 g/pill, 6 pills each time, three times a day.
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Qiyao Xiaoke Capsule (QXC)
Number of subjects: 116
Study: 20643442

Group type: EXPERIMENTAL
Intervention: Prophylactic procedure (nonresorbable figure‐of‐8 suture placed lateral to the internal ring of the inguinal canal)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Control (no prophylactic procedure)
Number of subjects: 294
Study: 19098692

Group type: EXPERIMENTAL
Intervention: Intramuscular acupuncture
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Periosteal acupuncture
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control group (information only)
Number of subjects: 144
Study: 15837441

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibition
Number of subjects: 0
Study: 11952186

Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nondepressed controls
Number of subjects: 0
Study: 9449727

Group type: EXPERIMENTAL
Intervention: Protective ventilation
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional ventilation
Number of subjects: 53
Study: 7703650

Group type: EXPERIMENTAL
Intervention: Education by a trained asthma nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not educated by a trained asthma nurse)
Number of subjects: 0
Study: 2655687

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Nitrendipine
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo phase
Number of subjects: 22

Group type: COMPARATOR
Intervention: Comparison of both agents
Number of subjects: 22
Study: 1274998

Group type: EXPERIMENTAL
Intervention: Synthetic reading instruction (parts-to-whole method)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Analytic reading instruction (whole-word method)
Number of subjects: 100
Study: 30278110

Group type: EXPERIMENTAL
Intervention: 1 L PEGA with PLD
Number of subjects: 173

Group type: COMPARATOR
Intervention: 2 L PEGA
Number of subjects: 173
Study: 29325337

Group type: EXPERIMENTAL
Intervention: Naloxone with ropivacaine (Group N)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ropivacaine (Group R)
Number of subjects: 70
Study: 26245675

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus Lapatinib
Number of subjects: 121

Group type: COMPARATOR
Intervention: Chemotherapy plus Trastuzumab or Lapatinib
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Dual anti-HER2 blockade (Trastuzumab and Lapatinib)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: 50-gene signature analysis
Number of subjects: 121
Study: 23354353

Group type: COMPARATOR
Intervention: Baby shampoo (Bübchen Kinder Shampoo)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Phospholipid-liposome solution (Blepha Cura)
Number of subjects: 53
Study: 21285986

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 30 mg/m² i.v. and Epirubicin (EPI) 30 mg/m² i.v. every week (D/EPI arm)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Docetaxel (D) 70 mg/m² i.v. every 3 weeks and Prednisone (P) 5 mg twice daily (D/P arm)
Number of subjects: 72
Study: 19632546

Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 90
Study: 16396667

Group type: EXPERIMENTAL
Intervention: Serotonin (releasing endogenous NO)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (SNP, exogenous NO-donor)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Calcitonin gene-related peptide (CGRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Flow-mediated dilation (FMD)
Number of subjects: 20
Study: 12851532

Group type: EXPERIMENTAL
Intervention: Intravenous heparin bolus
Number of subjects: 206

Group type: COMPARATOR
Intervention: No intravenous heparin bolus
Number of subjects: 206
Study: 10993997

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clozapine
Number of subjects: 15
Study: 8792695

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ranitidine HCI 150 mg twice daily
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ranitidine HCI 150 mg twice daily plus metoclopramide HCI 10 mg four times daily
Number of subjects: 290

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 290

Group type: COMPARATOR
Intervention: Ranitidine/metoclopramide
Number of subjects: 290

Group type: COMPARATOR
Intervention: Combination treatment (ranitidine + metoclopramide)
Number of subjects: 290
Study: 1620806

Group type: EXPERIMENTAL
Intervention: Opportunity to release negative affect
Number of subjects: 105

Group type: COMPARATOR
Intervention: No opportunity to release negative affect
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Anger-in tendencies in women
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Anger-out tendencies in women
Number of subjects: 105
Study: 6332178

Group type: EXPERIMENTAL
Intervention: High-dose infusion methotrexate (1,500 mg/m2) with leucovorin
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard-dose methotrexate (40 mg/m2) without leucovorin
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: High-dose infusion methotrexate
Number of subjects: 47

Group type: COMPARATOR
Intervention: Standard-dose methotrexate
Number of subjects: 47

Group type: COMPARATOR
Intervention: High-dose infusion methotrexate and Standard-dose methotrexate
Number of subjects: 47
Study: 31447547

Group type: EXPERIMENTAL
Intervention: Dextromethorphan (90 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/day)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dextromethorphan and Memantine
Number of subjects: 60
Study: 30181110

Group type: EXPERIMENTAL
Intervention: Siri, Alexa, or Google Assistant
Number of subjects: 54
Study: 25720659

Group type: EXPERIMENTAL
Intervention: Biobrane(®)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dressilk(®)
Number of subjects: 28

Group type: COMPARATOR
Intervention: PolyMem(®)
Number of subjects: 28
Study: 25243718

Group type: EXPERIMENTAL
Intervention: Food Prime
Number of subjects: 125

Group type: COMPARATOR
Intervention: No Prime
Number of subjects: 125
Study: 21689317

Group type: EXPERIMENTAL
Intervention: Doppler-guided transanal haemorrhoid dearterialization (THD)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Stapler haemorrhoidopexy (SH)
Number of subjects: 169
Study: 20456300

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Lansoprazole 30 mg
Number of subjects: 83

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg
Number of subjects: 83
Study: 16890417

Group type: EXPERIMENTAL
Intervention: Arm exercise
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Leg exercise
Number of subjects: 13
Study: 16251287

Group type: EXPERIMENTAL
Intervention: Pleconaril
Number of subjects: 827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 827
Study: 11867965

Group type: EXPERIMENTAL
Intervention: Clobetasol lotion under hydrocolloid occlusion once weekly
Number of subjects: 15

Group type: COMPARATOR
Intervention: Clobetasol ointment twice daily
Number of subjects: 15
Study: 10573105

Group type: EXPERIMENTAL
Intervention: MPEMi combination (Methotrexate, Cisplatin, Etoposide, Mitomycin)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MPEpiE combination (Methotrexate, Cisplatin, Epirubicin, Etoposide)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: MPEpiV combination (Methotrexate, Cisplatin, Epirubicin, Vincristine)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Pathologic complete response (pCR) in locally advanced disease
Number of subjects: 101
Study: 9201779

Group type: EXPERIMENTAL
Intervention: Caffeine (500 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 1747643

Group type: EXPERIMENTAL
Intervention: Caffeine free diet alone
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Caffeine free diet with caffeinated coffee
Number of subjects: 52

Group type: COMPARATOR
Intervention: Caffeine free diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Caffeine free diet with decaffeinated instant coffee
Number of subjects: 52

Group type: COMPARATOR
Intervention: Normal diet
Number of subjects: 52
Study: 7116588

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 28378441

Group type: EXPERIMENTAL
Intervention: Pedometer and step-monitoring diary (PED)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Pedometer and diary plus step targets (PED+)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Education (EDUC)
Number of subjects: 96
Study: 28641792

Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study: 26252485

Group type: EXPERIMENTAL
Intervention: NNC0109‐0012 (0.01, 0.05, 0.2, 0.6, 1.5, or 3.0 mg/kg single doses; 0.05, 0.2, 0.5, 1.0, or 2.0 mg/kg multiple doses every other week for 7 weeks; 2.0 mg/kg weekly doses for 7 weeks in expansion phase)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NNC0109‐0012
Number of subjects: 48
Study: 23723381

Group type: EXPERIMENTAL
Intervention: Proanthocyanidins (PA) treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glutaraldehyde (gold-standard cross-linker)
Number of subjects: 0
Study: 19793927

Group type: EXPERIMENTAL
Intervention: Double-bundle ACL reconstruction
Number of subjects: 70

Group type: COMPARATOR
Intervention: Single-bundle ACL reconstruction
Number of subjects: 70
Study: 18256415

Group type: EXPERIMENTAL
Intervention: Oral miltefosine (2.5 mg/kg/d for 28 days)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intramuscular antimony (20 mg/kg/d for 20 days)
Number of subjects: 57
Study: 16612915

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate (GTN) ointment, 0.2 percent, applied twice daily.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral nifedipine, 20 mg twice daily, retard formulation.
Number of subjects: 20
Study: 15322870

Group type: EXPERIMENTAL
Intervention: Streptococcus pneumoniae
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: H. influenzae
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: M. catarrhalis
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Pneumococci in otitis-prone children
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: General recommendation for antimicrobial therapy
Number of subjects: 74
Study: 10636106

Group type: EXPERIMENTAL
Intervention: Routine preoperative ERCP
Number of subjects: 60

Group type: COMPARATOR
Intervention: Selective postoperative ERCP
Number of subjects: 60
Study: 9111852

Group type: EXPERIMENTAL
Intervention: Combination of individual out-patient and family treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Individual out-patient treatment
Number of subjects: 0
Study: 8469463

Group type: EXPERIMENTAL
Intervention: Urinary LH assay
Number of subjects: 37

Group type: COMPARATOR
Intervention: Traditional timing methods (cycle‐averaging and/or review of basal body temperature graphs)
Number of subjects: 37
Study: 3897296

Group type: EXPERIMENTAL
Intervention: Indoprofen 100 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Indoprofen 200 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 3218878

Group type: EXPERIMENTAL
Intervention: Small-group, problem-solving sessions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional lectures
Number of subjects: 0

Group type: COMPARATOR
Intervention: Large-group, case discussions
Number of subjects: 0
Study: 31407484

Group type: EXPERIMENTAL
Intervention: Parecoxib sodium 40 mg before induction of anaesthesia, followed by 40 mg every 12 hours for 48 hours post-operation.
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo, administered 30 minutes before induction of anaesthesia, followed by placebo every 12 hours for 48 hours post-operation.
Number of subjects: 80
Study: 28793834

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT) with good therapist fidelity
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT) with below average therapist fidelity
Number of subjects: 72
Study: 26660722

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise with behavioural approach
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise without behavioural approach
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Neck-specific exercise (both groups combined)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Physical activity prescription
Number of subjects: 216
Study: 24302679

Group type: EXPERIMENTAL
Intervention: High flavanol chocolate (HFC)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Normal flavanol chocolate (NFC)
Number of subjects: 100
Study: 23820051

Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 0
Study: 20140437

Group type: EXPERIMENTAL
Intervention: Tolterodine 4 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Tolterodine 8 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 27948084

Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone (5 mg IV + 10 mg oral on days 1-5)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Generic ondansetron plus dexamethasone (24 mg IV + 10 mg oral on days 1-5)
Number of subjects: 41
Study: 16881245

Group type: EXPERIMENTAL
Intervention: In Our Own Voice (IOOV) presentation
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control presentation about psychology careers
Number of subjects: 114
Study: 15219521

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Coronary bypass graft surgery
Number of subjects: 0
Study: 10973155

Group type: EXPERIMENTAL
Intervention: 5,000 CCID50
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: 1,000 CCID50
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: 200 CCID50
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: All vaccine formulations
Number of subjects: 223
Study: 9213829

Group type: EXPERIMENTAL
Intervention: Heparansulphate 100 mg t.i.d.
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sulodexide 250 LSU b.i.d.
Number of subjects: 30
Study: 8448092

Group type: EXPERIMENTAL
Intervention: Obturator nerve block using 5 mL of 2.0% lidocaine followed by two or three prognostic blocks using 5 mL of 0.5% bupivacaine and 1:200,000 epinephrine, and final block with 5 mL of 6.0% phenol in glycerin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional approach to obturator nerve blockade
Number of subjects: 0
Study: 2876772

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C. parvum) administered intrapleurally and intravenously (7 mg injected into the pleural space and 7 mg intravenously once between days 6 and 12 postoperatively, followed by 7 mg intravenously every 3rd month during the 1st year)
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo (intrapleural administration of 35 cc of saline)
Number of subjects: 286

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum (C. parvum)
Number of subjects: 286
Study: 30661702

Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50000 IU weekly for 9 weeks)
Number of subjects: 619
Study: 29282609

Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum (5 × 10^7 cfu g−1)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Lactobacillus bulgaricus (5 × 10^7 cfu g−1)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei (5 × 10^7 cfu g−1)
Number of subjects: 480

Group type: COMPARATOR
Intervention: Control diet (without probiotics)
Number of subjects: 480
Study: 27046905

Group type: EXPERIMENTAL
Intervention: Dynamic cycling
Number of subjects: 47

Group type: COMPARATOR
Intervention: Static cycling
Number of subjects: 47
Study: 25378426

Group type: EXPERIMENTAL
Intervention: TMSsyn group (synchronous picture-naming training with contralesional 1 Hz-rTMS for 10 daily sessions)
Number of subjects: 45

Group type: COMPARATOR
Intervention: TMSsub group (subsequent picture-naming activity after primed 1 Hz-rTMS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: TMSsham group (concurrent naming task with sham 1 Hz-rTMS)
Number of subjects: 45
Study: 23213978

Group type: EXPERIMENTAL
Intervention: Comprehensive auricular acupuncture
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 90
Study: 20662329

Group type: EXPERIMENTAL
Intervention: Conventional Thriposha (cereal-based food with calcium and vitamin D3)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Corn-Soya-Blend (CSB) without mineral and vitamin premix
Number of subjects: 60
Study: 18309461

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Carvedilol + Enalapril
Number of subjects: 3

Group type: COMPARATOR
Intervention: Carvedilol
Number of subjects: 3
Study: 16042514

Group type: EXPERIMENTAL
Intervention: 4 education sessions using a medical simulator
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wait-list control group (no intervention initially)
Number of subjects: 0
Study: 12270567

Group type: EXPERIMENTAL
Intervention: Metronidazole 100mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Metronidazole 250mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Metronidazole 500mg
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 10602101

Group type: EXPERIMENTAL
Intervention: Color Doppler imaging
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gray-scale sonography
Number of subjects: 20
Study: 15321258

Group type: EXPERIMENTAL
Intervention: 0.3 mg diamorphine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline with bupivacaine 0.5% in 8% dextrose (Control)
Number of subjects: 40
Study: 8476582

Group type: EXPERIMENTAL
Intervention: Ofloxacin 400 mg once daily for 7-14 days
Number of subjects: 319

Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice daily for 7-14 days
Number of subjects: 319